JAMA Oncology· 2020Q1
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- 1,215citations
- Q1SCImago
- 2020year
Short summary
In patients with advanced liver cancer previously treated with sorafenib, the combination of nivolumab and ipilimumab demonstrated an objective response rate of up to 32% and durable responses, leading to accelerated US approval for the arm A regimen.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine